News - Appointments

Mats Blom has become chief financial officer at the Dutch biotech NorthSea Therapeutics BV which is developing treatments for metabolic and fibrotic diseases including nonalcoholic steatohepatitis (NASH).

Stewart Kay, formerly of GlaxoSmithKline Plc, has joined Crescendo Biologics Ltd as chief business officer as the company advances its lead product towards the clinic.

Jens Schneider-Mergener, a serial entrepreneur, has become chief executive officer of Adrenomed AG, a privately financed company with a lead product for septic shock. He  succeeds Gerald Möller, who joins Adrenomed’s Supervisory Board.

Steven Romano, a board-certified psychiatrist, has joined by board of Silence Therapeutics Plc as a non-executive director to help oversee the company’s RNA therapeutics for the treatment of serious diseases.

The academic and drug development expert Bams Abila has joined Immodulon Therapeutics Ltd as chief medical officer to help the company progress its lead drug candidate for cancer.

Zealand Pharma A/S has appointed Matthew Dallas as its chief financial officer, effective 7 October, to oversee the commercialisation of its peptide-based medicines.

Tissue Regenix Group, a regenerative medical devices group, has appointed Mike Barker as chief financial officer. He has been interim CFO since the start of 2019.

James Phillips, a physician and biopharma executive, is to become chief executive of Paion AG on 16 October succeeding the company’s co-founder and CEO Wolfgang Söhngen who is retiring.

The regulatory consultancy NDA Group has appointed Robert Kronqvist as general manager for its Nordic affiliate headquartered in Stockholm, to help biotech companies bring their products through registration and onto the market.

Klaas Bakker, a former executive at AstraZeneca Plc, is to join Oncopeptides AB as chief medical officer in November to help the company manage a global, confirmatory Phase 3 trial of its peptide conjugate melflufen for multiple myeloma.